Nucleic acid comprising GlXmGn as an immune-stimulating agent/adjuvant

Patent metadata

Field	Value
Publication number	US-10441653-B2
Application number	US-201213492787-A
Country	US
Kind code	B2
Filing date	Jun 8, 2012
Priority date	Jul 31, 2006
Publication date	Oct 15, 2019
Grant date	Oct 15, 2019

Abstract

The present invention relates to a nucleic acid of the general formula (I): GIXmGn, which may be modified by a lipid. The invention relates further to a pharmaceutical composition containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). The present invention can relate to a vaccine, which corresponds to a pharmaceutical composition of the invention, wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention can relate to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune disease, allergies or cancer diseases.

First claim

The invention claimed is:

1. A method of stimulating an immune response to a disease antigen, comprising administering to a patient in need thereof a composition comprising:
(a) the disease antigen or nucleic acid encoding a disease antigen; and
(b) a pharmaceutically effective amount of an adjuvant nucleic acid, wherein the adjuvant nucleic acid comprises at least one adjuvant nucleic acid sequence selected from the following sequences:

(SEQ ID NO: 1)

GGUUUUUUUUUUUUUUUGGG;

(SEQ ID NO: 2)

GGGGGUUUUUUUUUUGGGGG;

(SEQ ID NO: 3)

GGGGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGGGG;

(SEQ ID NO: 4)

GUGUGUGUGUGUUUUUUUUUUUUUUUUGUGUGUGUGUGU;

(SEQ ID NO: 5)

GGUUGGUUGGUUUUUUUUUUUUUUUUUGGUUGGUUGGUU;

(SEQ ID NO: 10)

GGGGGGUUUUUUUUGGGGGG;

(SEQ ID NO: 11)

GGGGGGUUUUUUUUUGGGGG;

(SEQ ID NO: 12)

GGGGGGUUUUUUUUUUGGGG;

(SEQ ID NO: 13)

GGGGGUUUUUUUUUUUGGGG;

(SEQ ID NO: 14)

GGGGGUUUUUUUUUUUUGGG;

(SEQ ID NO: 15)

GGGGUUUUUUUUUUUUUGGG;

(SEQ ID NO: 16)

GGGGUUUUUUUUUUUUUUGG;

(SEQ ID NO: 17)

GGUUUUUUUUUUUUUUUUGG;

(SEQ ID NO: 18)

GUUUUUUUUUUUUUUUUUUG;

(SEQ ID NO: 23)

GGGGGGGUUUUUUUUGGGGGGG;

(SEQ ID NO: 24)

GGGGGGGUUUUUUUUUGGGGGG;

(SEQ ID NO: 25)

GGGGGGGUUUUUUUUUUGGGGG;

(SEQ ID NO: 26)

GGGGGGUUUUUUUUUUUGGGGG;

(SEQ ID NO: 27)

GGGGGGUUUUUUUUUUUUGGGG;

(SEQ ID NO: 28)

GGGGGUUUUUUUUUUUUUGGGG;

(SEQ ID NO: 29)

GGGGGUUUUUUUUUUUUUUGGG;

(SEQ ID NO: 30)

GGGUUUUUUUUUUUUUUUUGGG;

(SEQ ID NO: 31)

GGUUUUUUUUUUUUUUUUUUGG;

(SEQ ID NO: 36)

GGGGGGGGUUUUUUUUGGGGGGGG;

(SEQ ID NO: 37)

GGGGGGGGUUUUUUUUUGGGGGGG;

(SEQ ID NO: 38)

GGGGGGGGUUUUUUUUUUGGGGGG;

(SEQ ID NO: 39)

GGGGGGGUUUUUUUUUUUGGGGGG;

(SEQ ID NO: 40)

GGGGGGGUUUUUUUUUUUUGGGGG;

(SEQ ID NO: 41)

GGGGGGUUUUUUUUUUUUUGGGGG;

(SEQ ID NO: 42)

GGGGGGUUUUUUUUUUUUUUGGGG;

(SEQ ID NO: 43)

GGGGUUUUUUUUUUUUUUUUGGGG;

(SEQ ID NO: 44)

GGGUUUUUUUUUUUUUUUUUUGGG;

(SEQ ID NO: 45)

GUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUG;

(SEQ ID NO: 46)

GGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGG;

(SEQ ID NO: 47)

GGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGG;

(SEQ ID NO: 48)

GGGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGG;

(SEQ ID NO: 49)

GGGGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGGG;

(SEQ ID NO: 50)

GGGGGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGGGG;

(SEQ ID NO: 51)

GGGGGGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGGGGG;

(SEQ ID NO: 52)

GGGGGGGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGGGGGG;

(SEQ ID NO: 53)

GGGGGGGGGUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUGGGGGGGG;

(SEQ ID NO: 59)

GGUUUUUUUUGG;

(SEQ ID NO: 60)

GGUUUUUUUUUGG;

(SEQ ID NO: 61)

GGUUUUUUUUUUGG;

(SEQ ID NO: 62)

GGUUUUUUUUUUUGG;

(SEQ ID NO: 63)

GGUUUUUUUUUUUUGG;

(SEQ ID NO: 64)

GGUUUUUUUUUUUUUGG;

Assignees

• Hoerr Ingmar
• Probst Jochen
• Ketterer Thomas
• Scheel Birgit
• Curevac Ag

Inventors

• Hoerr Ingmar
• Probst Jochen
• Ketterer Thomas
• Scheel Birgit

Classifications

• C12N15/117

  Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P35/02

  specific for leukemia · CPC title